Ranbaxy Recalls Nitrofurantoin From U.S. Due to Remote Possibility Of Non-conformity And Adverse Reactions
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - In yet another move that could raise doubts about the quality of its drugs, Ranbaxy has announced a voluntary recall of its antibiotic nitrofurantoin capsules from the U.S. market. This is the second voluntary drug recall made by Ranbaxy in two years, the first being gabapentin tablets called back in 2007